Stryker Corporation (SYK)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$326.91-0.86%
Close 2026-07-08 · 1-day change
Reading SYK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SYK free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading SYK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SYK free→QuarterlyIQ Insights · SYK
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 14 valuation methods, at three horizons. Current price $326.91. As of 2026-07-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $327 SYK trades at 24× p/e, below its 36× p/e peer median, but our blended $325 fair value is roughly in line with the price. It's a high-confidence read. Analysts target $315–$418. Not investment advice.
$315.00 – $418.00 (median $374.00) · 12 analysts · as of 2026-07-08
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 80% over what the business is worth with no growth; closing that gap needs roughly 9.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $9.86/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2025-Q4, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $374.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $506.08 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $512.90 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $59.18 | — | — | TTM | high |
| graham number | 12M | $133.84 | — | — | TTM | high |
| Mgmt guidance | 12M | $538.02 | 35.9 | 15.00 | Mgmt | high |
| Peer EV/EBITDA | 12M | $55.30 | 6.0 | 14.42 | TTM | high |
| Peer P/FCF | 12M | $278.53 | 23.6 | 11.83 | TTM | high |
| Peer P/E | 12M | $480.28 | 35.9 | 13.39 | TTM | high |
| Peer P/S | 12M | $177.29 | 2.7 | 65.38 | TTM | high |
| PEG | 12M | $440.05 | 32.9 | 13.39 | TTM | high |
| residual income | 12M | $91.98 | — | — | TTM | high |
| Own P/E history | 12M | $351.89 | 26.3 | 13.39 | TTM | high |
| triangulated | 12M | $484.93 | 35.9 | 13.52 | Triangulated | high |
| Mgmt guidance | 3Y | $844.48 | 35.9 | 23.54 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $423.62 | 23.6 | 17.99 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $685.05 | 35.9 | 19.10 | Analyst | medium |
| Peer P/S | 3Y | $237.02 | 2.7 | 87.41 | guidance | medium |
| PEG | 3Y | $627.68 | 32.9 | 19.10 | Analyst | medium |
| Own P/E history | 3Y | $501.93 | 26.3 | 19.10 | Analyst | medium |
| Mgmt guidance | 5Y | $1140.56 | 35.9 | 31.80 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $560.23 | 23.6 | 23.79 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $810.18 | 35.9 | 22.59 | Analyst | high |
| Peer P/S | 5Y | $280.31 | 2.7 | 103.38 | guidance | high |
| PEG | 5Y | $742.33 | 32.9 | 22.59 | Analyst | high |
| Own P/E history | 5Y | $593.61 | 26.3 | 22.59 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.